<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1075</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2026-21-3-113-126</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CURRENT BASIC RESEARCH IN HEMATOLOGY AND PRACTICAL MEDICINE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ФУНДАМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ В ОНКОГЕМАТОЛОГИИ И ПРАКТИЧЕСКОЙ МЕДИЦИНЕ НА СОВРЕМЕННОМ ЭТАПЕ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Differentially expressed genes in CD34<sup>+</sup> cells in Ph-negative myeloproliferative neoplasms: bioinformatics meta-analysis of three independent studies</article-title><trans-title-group xml:lang="ru"><trans-title>Дифференциально экспрессируемые гены в CD34<sup>+</sup>-клетках при Ph-негативных миелопролиферативных новообразованиях: биоинформационный метаанализ результатов 3 независимых исследований</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4555-7457</contrib-id><name-alternatives><name xml:lang="en"><surname>Timechko</surname><given-names>E. E.</given-names></name><name xml:lang="ru"><surname>Тимечко</surname><given-names>Е. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>krashemcenter@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-0479-126X</contrib-id><name-alternatives><name xml:lang="en"><surname>Yakimov</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Якимов</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>krashemcenter@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2269-0298</contrib-id><name-alternatives><name xml:lang="en"><surname>Tyumentseva</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Тюменцева</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>krashemcenter@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8037-9844</contrib-id><name-alternatives><name xml:lang="en"><surname>Stolyar</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Столяр</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>krashemcenter@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8756-2660</contrib-id><name-alternatives><name xml:lang="en"><surname>Gorbenko</surname><given-names>A.  S.</given-names></name><name xml:lang="ru"><surname>Горбенко</surname><given-names>А. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>krashemcenter@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2311-2219</contrib-id><name-alternatives><name xml:lang="en"><surname>Olkhovskiy</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Ольховский</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>krashemcenter@mail.ru</email><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Prof. V. F. Voino-Yasenetsky Krasnoyarsk State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В. Ф. Войно-Ясенецкого» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Federal Research Center “Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences”</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Федеральный исследовательский центр «Красноярский научный центр Сибирского отделения Российской академии наук»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Krasnoyarsk Branch of the National Medical Research Center for Hematology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">Красноярский филиал ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-09-30" publication-format="electronic"><day>30</day><month>09</month><year>2026</year></pub-date><volume>21</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>113</fpage><lpage>126</lpage><history><date date-type="received" iso-8601-date="2025-12-18"><day>18</day><month>12</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, ABV-press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, АБВ-­пресс</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">ABV-press</copyright-holder><copyright-holder xml:lang="ru">АБВ-­пресс</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://oncohematology.abvpress.ru/ongm/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/1075">https://oncohematology.abvpress.ru/ongm/article/view/1075</self-uri><abstract xml:lang="en"><p>Accumulating evidence suggests that the molecular pathobiology of Ph-negative myeloproliferative neoplasms (MPNs) is significantly more complex than expected, with associated somatic mutations failing to fully explain the underlying causes and maintaining a high degree of uncertainty regarding individual disease prognosis. Given the involvement of epigenetic mechanisms of carcinogenesis in altered gene expression, attempts have been made to identify specific transcriptome alterations in hematopoietic cells in MPNs. However, these results often inconsistently reflect the use of different analytical technologies, statistical approaches, and the small number of patients included.</p> <p>Aim – to perform a bioinformatics meta-analysis of available databases of primary results from microarray studies of CD34<sup>+</sup> cell RNA profiling in patients with MPNs.</p> <p>The NCBI GEO catalog was used to search for raw data. After searching for the keyword “myeloproliferative neoplasm”, three independent databases were identified that matched the Affymetrix analytical platform and biomaterial type. Processing was performed in the integrated RStudio development environment using the oligo package. Gene expression normalization was performed using the robust multiarray average method. Differential gene expression analysis in CD34<sup>+</sup> cells between patient groups was performed using the limma package. To enhance the reliability of the results, a meta-analysis was performed using a combination of Fisher’s and Stauffer’s methods, with the Jackknife procedure used for final filtering.</p> <p>The meta-analysis identified 33 genes common to MPN, as well as 7, 204, and 1806 genes specific to essential thrombocythemia, polycythemia vera, and primary myelofibrosis, respectively, that were differentially expressed. The <italic>PIM1</italic> gene expression level significantly varied in the series control → essential thrombocythemia → polycythemia vera → primary myelofibrosis. The functional annotation confirms the pathogenetic mechanisms of the disease: impaired DNA repair, apoptosis, proliferative and functional activation, and the development of inflammatory processes in the bone marrow. It also demonstrates the multilevel nature of the interactions between intracellular signaling pathways and the pleiotropy of regulatory processes in carcinogenesis. Overall, the obtained data are consistent with Dameshek’s biological continuum postulate, which suggests a single pathogenetic mechanism for the evolution of MPNs.</p></abstract><trans-abstract xml:lang="ru"><p>Накапливающиеся данные свидетельствуют о том, что молекулярная патобиология Ph-негативных миелопролиферативных новообразований (МПН) гораздо сложнее, чем ожидалось, а сопутствующие соматические мутации не могут полностью объяснить первопричины и сохраняют высокую степень неопределенности индивидуального прогноза заболевания. С учетом вовлеченности эпигенетических механизмов нарушения экспрессии множества генов предпринимаются попытки поиска специфических изменений транскриптома кроветворных клеток при МПН, вместе с тем их результаты часто не совпадают вследствие использования различных аналитических технологий, статистических подходов и небольших выборок пациентов.</p> <p>Цель работы – биоинформационный метаанализ доступных баз данных первичных результатов исследований профиля РНК в CD34<sup>+</sup>-клетках методами микрочипирования у пациентов с МПН.</p> <p>Поиск исходных данных проводили в каталоге NCBI GEO. После отбора по ключевым словам myeloproliferative neoplasm выделены 3 независимые базы данных, совпадающие по аналитической платформе Affymetrix и типу биоматериала. Процессинг проводили в интегрированной среде разработки RStudio с использованием пакета oligo, нормализацию генной экспрессии осуществляли методом robust multiarray average, анализ дифференциальной экспрессии генов в CD34<sup>+</sup>-клетках между группами пациентов проводили с использованием пакета limma. Для повышения надежности результатов метаанализ проводили с использованием комбинации методов Фишера и Стауфера, а в финальной фильтрации использовали процедуру Jackknife.</p> <p>Результаты метаанализа позволили выделить 33 дифференциально экспрессированных гена, общих для МПП, а также 7, 204 и 1806 генов, характерных соответственно для эссенциальной тромбоцитемии, истинной полицитемии и первичного миелофиброза. Уровень экспрессии гена <italic>PIM1</italic> значимо различался в ряду контроль → эссенциальная тромбоцитемия → истинная полицитемия → первичный миелофиброз. Функциональная аннотация подтверждает патогенетические механизмы заболевания: нарушение репарации ДНК, апоптоза, пролиферативной и функциональной активации, развитие воспалительных процессов в костном мозге – и свидетельствует о многоуровневом характере взаимодействия внутриклеточных сигнальных путей и плейотропности регуляторных процессов канцерогенеза. В целом полученные данные соответствуют постулату биологического континуума W. Dameshek, предполагающего единый патогенетический механизм эволюции МПН.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Ph-negative myeloproliferative neoplasm</kwd><kwd>bioinformatics analysis</kwd><kwd>transcriptome</kwd><kwd>CD34+ cell</kwd><kwd>Affymetrix microarray</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>Ph-негативное миелопролиферативное новообразование</kwd><kwd>биоинформационный анализ</kwd><kwd>транскриптом</kwd><kwd>CD34+-клетка</kwd><kwd>микрочип Affymetrix</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Российский научный фонд</institution></institution-wrap><institution-wrap><institution xml:lang="en">Russian Science Foundation</institution></institution-wrap></funding-source><award-id>25-15-00094</award-id></award-group><funding-statement xml:lang="en">This research was funded by the Russian Science Foundation No. 25-15-00094 (https://rscf.ru/project/25-15-00094/)</funding-statement><funding-statement xml:lang="ru">Исследование выполнено за счет гранта Российского научного фонда № 25-15-00094 (https://rscf.ru/project/25-15-00094/)</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Меликян А.Л., Суборцева И.Н., Ковригина А.М., и др. Национальные клинические рекомендации по диагностике и лечению Ph-негативных миелопролиферативных новообразований (истинной полицитемии, эссенциальной тромбоцитемии, первичного миелофиброза) (редакция 2024 г.). Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2024;17(3):291–334. DOI: 10.21320/2500-2139-2024-17-3-291-334.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Melikyan A.L., Subortseva I.N., Kovrigina A.M., et al. National Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis) (Edition 2024). Clinical Oncohematology. Basic Research and Clinical Practice. 2024;17(3):291–334. DOI: 10.21320/2500-2139-2024-17-3-291-334. (in Russian)</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Melo-Cardenas J., Migliaccio A.R., Crispino J.D. The Role of Megakaryocytes in Myelofibrosis. Hematol Oncol Clin North Am. 2021;35(2):191-203. PMID: 33641863. DOI: 10.1016/j.hoc.2020.11.004</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Dameshek W. Some speculations on the myeloproliferative syndromes [editorial]. Blood. 1951;6(4):372-375. PMID: 26869302. DOI: 10.1182/blood-2015-12-686402.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Grinfeld J., Nangalia J., Green A.R. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica. 2017;102(1):7-17. PMID: 27909216, DOI: 10.3324/haematol.2014.113845</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Skov V., Thomassen M., Riley C.H., et al. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol. 2012;40(9):771-780.e19. PMID: 22659388. DOI: 10.1016/j.exphem.2012.05.011.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Wong W.J., Baltay M., Getz A., et al. Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures. PLoS One. 2019;14(5):e0216810. PMID: 31071164. DOI: 10.1371/journal.pone.0216810.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Pardanani A., Lasho T.L., Finke C., et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007 Sep;21(9):1960-3. PMID: 17597810. DOI: 10.1038/sj.leu.2404810.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Luque Paz D., Kralovics R., Skoda R.C. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023;141(16):1909-1921. PMID: 36347013. DOI: 10.1182/blood.2022017578.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Меликян А.Л., Суборцева И.Н. Биология миелопролиферативных новообразований. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2016;9(3):314–325. DOI:10.21320/2500-2139-2016-9-3-314-325.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Melikyan A.L., Subortseva I.N. Biology of Myeloproliferative Malignancies. Clinical Oncohematology. Basic Research and Clinical Practice. 2016;9(3):314–325. DOI: 10.21320/2500-2139-2016-9-3-314-325. (in Russian)</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Čokić V.P., Mossuz P., Han J., et al. Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway. PLoS One. 2015;10(8):e0135463. PMID: 26275051. DOI: 10.1371/journal.pone.0135463.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Baumeister J., Maié T., Chatain N., et al. Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells. Ann Hematol. 2021;100(12):2943-2956. PMID: 34390367. DOI: 10.1007/s00277-021-04615-8.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Tenedini E., Fagioli M.E., Vianelli N., et al. Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. Blood. 2004;104(10):3126-35. PMID: 15271793. DOI: 10.1182/blood-2003-07-2597.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Walter W., Nadarajah N., Hutter S., et al. Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase. Leukemia. 2024;38(12):2644-2652. PMID: 39341969. DOI: 10.1038/s41375-024-02425-1.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Li S., Wu S., Xu M., et al. Potential application of the bulk RNA sequencing in routine MPN clinics. BMC Cancer. 2025;25(1):746. PMID: 40264064. DOI: 10.1186/s12885-025-13947-x.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Barrett T., Wilhite S.E., Ledoux P., et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991-5. PMID: 23193258. DOI: 10.1093/nar/gks1193.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Carvalho B.S., Irizarry R.A. A framework for oligonucleotide microarray preprocessing. Bioinformatics. 2010;26(19):2363-7. PMID: 20688976. DOI: 10.1093/bioinformatics/btq431.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Bolstad B.M., Irizarry R.A., Astrand M., Speed T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19(2):185-93. PMID: 12538238. DOI: 10.1093/bioinformatics/19.2.185.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Ritchie M.E., Phipson B., Wu D., et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. PMID: 25605792. DOI: 10.1093/nar/gkv007.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kotz S., Johnson N.L. (eds) Breakthroughs in Statistics. Springer Series in Statistics. New York: Springer, 1992, 628 pp.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Stouffer S.A., Lumsdaine A.A., Lumsdaine M.H., et al. The American soldier: Combat and its aftermath. (Studies in social psychology in World War II). Princeton University Press., 1949.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Пакет «statannotations». Доступно по: https://statannotations.readthedocs.io/en/latest/statannotations.html</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>ShinyGO 0.85.1. Доступно по: https://bioinformatics.sdstate.edu/go/</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>StringDB. Доступно по: https://string-db.org</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Wickham H. ggplot2. Elegant Graphics for Data Analysis. New York: Springer, 2009.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Wu S., Li Z., Gnatenko D.V., et al. BLVRB redox mutation defines heme degradation in a metabolic pathway of enhanced thrombopoiesis in humans. Blood. 2016;128(5):699-709. PMID: 27207795. DOI: 10.1182/blood-2016-02-696997.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Nesbitt N.M., Araldi G.L., Pennacchia L., et al. Small molecule BLVRB redox inhibitor promotes megakaryocytopoiesis and stress thrombopoiesis in vivo. Nat Commun. 2025;16(1):3480. PMID: 40216753. DOI: 10.1038/s41467-025-58497-9.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Xie S., Wu F., Zhao X. et al. MED16 Negatively Regulates Erythropoiesis and Myelopoiesis through Modulation of Chromatin Accessibility. 65th ASH Annual Meeting Abstracts. 2023;142(Supp. 1): 2673.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Mukherjee K., Bieker J.J. Transcriptional Control of Gene Expression and the Heterogeneous Cellular Identity of Erythroblastic Island Macrophages. Front Genet. 2021;12:756028. PMID: 34880902. DOI: 10.3389/fgene.2021.756028.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Fan W., Cao W., Shi J., et al. Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2V617F mutation. Ann Hematol. 2023;102(7):1745-1759. PMID: 37233774. DOI: 10.1007/s00277-023-05284-5.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>HSPBP1 Phenotypes with the most-significant associations for this locus. Доступно по: https://koges.leelabsg.org/region/KoGES_PLT/gene/HSPBP1</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Spi vak J.L., Jie C., Williams D., Moliterno A.R. JAK2V671F, Gender and the Gene Expression Profile of Polycythemia Vera. Blood. 2008;112(11):2805–2805. DOI: 10.1182/blood.V112.11.2805.2805.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Noetzli L., Parvin S., Battinelli E., Machlus K. CCL5 Enhances Megakaryocyte Differentiation and Development. Blood [Internet]. 2018;132(Supplement 1):522–522.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Yoshioka S., Okimura Y., Takahashi Y., et al. Up-regulation of mitochondrial transcription factor 1 mRNA levels by GH in VSMC. Life Sci. 2004;74(17):2097-109. PMID: 14969715, DOI: 10.1016/j.lfs.2003.07.057.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Caiado F., Pietras E.M., Manz M.G. Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection. J Exp Med. 2021;218(7):e20201541. PMID: 34129016. DOI: 10.1084/jem.20201541</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Rice K.L., Lin X., Wolniak K., et al. Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer J. 2011;1(11):e40. PMID: 22829077. DOI: 10.1038/bcj.2011.39.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Nakazawa H., Kaiume H., Igarashi K., et al. A Diagnostic Impact of Serum Autotaxin Levels in Patients with Bone Marrow Fibrosis. Clin Lymphoma Myeloma Leuk. 2023;23(2):e117-e124. PMID: 36567212. DOI: 10.1016/j.clml.2022.12.006.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Patent US10632104B2 Autotaxin inhibitors and uses thereof. BainJillian G., EvansJohn F., Hutchinson H., Lonergan D. Опубл. 08.12.2011.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Lally J., Boasman K., Brown L., et al. GATA-1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis. J Thromb Haemost. 2019;17(6):896-900. PMID: 30889303. DOI: 10.1111/jth.14433.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Kelliher S., Gamba S., Weiss L., et al. Platelet proteomic profiling reveals potential mediators of immunothrombosis and proteostasis in myeloproliferative neoplasms. Blood Adv. 2024;8(16):4276-4280. PMID: 38861353. DOI: 10.1182/bloodadvances.2023012016.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Falanga A., Marchetti M., Russo L. Hemostatic Biomarkers and Cancer Prognosis: Where Do We Stand? Semin Thromb Hemost. 2021;47(8):962-971. PMID: 34450680. DOI: 10.1055/s-0041-1733925.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Barneda-Zahonero B., Román-González L., Collazo O., et al. HDAC7 is a repressor of myeloid genes whose downregulation is required for transdifferentiation of pre-B cells into macrophages. PLoS Genet. 2013;9(5):e1003503. PMID: 23696748. DOI: 10.1371/journal.pgen.1003503.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Wang P., Wang Z., Liu J. Role of HDACs in normal and malignant hematopoiesis. Mol Cancer. 2020;19(1):5. PMID: 31910827. DOI: 10.1186/s12943-019-1127-7.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Visconte V., Rogers H.J., Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood. 2012;120(16):3173-86. PMID: 22826563. DOI: 10.1182/blood-2012-05-430876.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Joehanes R., Johnson A.D., Barb J.J., et al. Gene expression analysis of whole blood, peripheral blood mononuclear cells, and lymphoblastoid cell lines from the Framingham Heart Study. Physiol Genomics. 2012;44(1):59-75. PMID: 22045913. DOI: 10.1152/physiolgenomics.00130.2011.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Dunbar A.J., Kim D., Lu M., et al. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis. Blood. 2023;141(20):2508-2519. PMID: 36800567. DOI: 10.1182/blood.2022015418.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Skov V., Thomassen M., Kjaer L., et al. Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms. Eur J Haematol. 2023;111(5):805-814. PMID: 37640394. DOI: 10.1111/ejh.14081.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Lee S.H., Lin C.C., Wei C.H., et al. PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients. J Pathol Clin Res. 2022;8(1):78-87. PMID: 34480529. DOI: 10.1002/cjp2.240.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Wang J.C., Sun L. PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review. Int J Mol Sci. 2022;23(10):5837. PMID: 35628647. DOI: 10.3390/ijms23105837.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Tefferi A., Vaidya R., Caramazza D., et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356-63. PMID: 21300928. DOI: 10.1200/JCO.2010.32.9490.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Nock S., Karim E., Unsworth A.J. Pim Kinases: Important Regulators of Cardiovascular Disease. Int J Mol Sci. 2023;24(14):11582. PMID: 37511341. DOI: 10.3390/ijms241411582.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Huang S.M., Wang A., Greco R., et al. Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance. Oncotarget. 2014;5(10):3362-74. PMID: 24830942. DOI: 10.18632/oncotarget.1951.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Bellon M., Nicot C. Targeting Pim kinases in hematological cancers: molecular and clinical review. Mol Cancer. 2023;22(1):18. PMID: 36694243. DOI: 10.1186/s12943-023-01721-1.</mixed-citation></ref></ref-list></back></article>
